Palvella Therapeutics, Inc.
PVLA
$50.13
-$3.29-6.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 181.86% | 389.94% | 154.25% | 311.38% | 49.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.09% | 347.47% | 208.33% | 225.95% | -33.30% |
| Operating Income | -218.09% | -347.47% | -208.33% | -225.95% | 33.30% |
| Income Before Tax | -127.01% | -222.75% | -119.24% | -139.23% | -154.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.01% | -222.75% | -119.24% | -139.23% | -154.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.01% | -222.75% | -119.24% | -139.23% | -154.21% |
| EBIT | -218.09% | -347.47% | -208.33% | -225.95% | 33.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 65.26% | 51.81% | -127.71% | -130.32% | -887.74% |
| Normalized Basic EPS | 63.64% | 48.12% | -14.06% | -119.20% | -275.17% |
| EPS Diluted | 65.26% | 51.81% | -127.71% | -130.32% | -895.61% |
| Normalized Diluted EPS | 63.64% | 48.12% | -14.06% | -119.20% | -278.74% |
| Average Basic Shares Outstanding | 524.38% | 522.17% | 92.52% | 0.00% | -69.05% |
| Average Diluted Shares Outstanding | 524.38% | 522.17% | 92.52% | 0.00% | -69.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |